Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Other Accumulated Expenses: 2020-2025

Historic Other Accumulated Expenses for Beam Therapeutics (BEAM) over the last 5 years, with Sep 2025 value amounting to $2.7 million.

  • Beam Therapeutics' Other Accumulated Expenses rose 5.28% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year increase of 5.28%. This contributed to the annual value of $7.8 million for FY2024, which is 72.73% down from last year.
  • Latest data reveals that Beam Therapeutics reported Other Accumulated Expenses of $2.7 million as of Q3 2025, which was up 21.13% from $2.2 million recorded in Q2 2025.
  • In the past 5 years, Beam Therapeutics' Other Accumulated Expenses ranged from a high of $28.6 million in Q4 2023 and a low of $2.2 million during Q2 2025.
  • In the last 3 years, Beam Therapeutics' Other Accumulated Expenses had a median value of $7.5 million in 2023 and averaged $11.0 million.
  • In the last 5 years, Beam Therapeutics' Other Accumulated Expenses skyrocketed by 212.95% in 2024 and then tumbled by 90.49% in 2025.
  • Quarterly analysis of 5 years shows Beam Therapeutics' Other Accumulated Expenses stood at $7.0 million in 2021, then spiked by 76.08% to $12.3 million in 2022, then spiked by 133.58% to $28.6 million in 2023, then slumped by 72.73% to $7.8 million in 2024, then increased by 5.28% to $2.7 million in 2025.
  • Its Other Accumulated Expenses stands at $2.7 million for Q3 2025, versus $2.2 million for Q2 2025 and $3.4 million for Q1 2025.